ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
In-silico FDA-approved drug repurposing to find the possible treatment of Coronavirus Disease-19 (COVID-19).pdf (1.04 MB)

In-Silico FDA-Approved Drug Repurposing to Find the Possible Treatment of Coronavirus Disease-19 (COVID-19)

preprint
submitted on 20.05.2020 and posted on 21.05.2020 by Kumar Sharp, Dr. Shubhangi Dange
Identification of potential drug-target interaction for approved drugs serves as the basis of repurposing drugs. Studies have shown polypharmacology as common phenomenon. In-silico approaches help in screening large compound libraries at once which could take years in a laboratory. We screened a library of 1050 FDA-approved drugs against spike glycoprotein of SARS-CoV2 in-silico. Anti-cancer drugs have shown good binding affinity which is much better than hydroxychloroquine and arbidol. We have also introduced a hypothesis named “Bump” hypothesis which and be developed further in field of computational biology.

History

Email Address of Submitting Author

dangeshubhangi@gmail.com

Institution

Government Medical College and Hospital, Jalgaon

Country

India

ORCID For Submitting Author

0000-0003-1483-1449

Declaration of Conflict of Interest

None

Version Notes

Kindly send all corresponding to: Dr. Shubhangi Dange Associate Professor Department of Microbiology, Government Medical College and Hospital Jalgaon dangeshubhangi@gmail.com

Exports